Printer Friendly
The Free Library
14,574,814 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Company Profile for Vasomedical, Inc.


Vasomedical, Inc. develops, manufactures and markets EECP(R) therapy systems to deliver its proprietary form of enhanced external counterpulsation therapy. EECP(R) therapy is a non-invasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve exercise performance and quality of life for thousands of people worldwide. For more information, visit www.vasomedical.com.

Company:               <
Vasomedical, Inc.
                       <

Headquarters Address:  <
180 Linden Avenue
                       <
Westbury, NY 11590
                       <

Main Telephone:        <
516-997-4600
                       <

Website:               <
www.vasomedical.com
                       <

Ticker:                <
VASO(OTCBB)
                       <

Type of Organization:  <
Public
                       <

Industry:              <
Medical Devices
                       <

Key Executives:        <
Chairman: Abraham Cohen
                       <
Vice Chairman: John Hui
                       <
President & CEO: Jun Ma
                       <

Public Relations       <

Contact:               <
Kasia Smigielska
Phone:                 <
516-997-4600 ext. 184
Email:                 <
ksmig@vasomedical.com
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Company overview
Date:Nov 6, 2008
Words:176
Previous Article:USG Corporation to Participate in the CL King & Associates Best Ideas Conference 2008 in New York.(Conference news)
Next Article:Company Profile for BancInsure.(Company overview)
Topics:



Related Articles
IEPR CONFIRMS EFFECTIVENESS OF VASOMEDICAL'S EECP THERAPY.(Brief Article)
VASOMEDICAL REPORTS 118% NET INCOME INCREASE IN SECOND QUARTER.(sales information)(Brief Article)(Statistical Data Included)
VASOMEDICAL'S EECP THERAPY REDUCES ANGINA SEVERITY.(Brief Article)
VASOMEDICAL HAD NET LOSS OF $695,000 OR $0.01 PER COMMON SHARE.
Vasomedical Announces a New Strategic Alliance with Living Data Technology Corp.
Vasomedical Reports First Quarter Fiscal 2008 Financial Results.(Financial report)
Medicare Increases Rates for Vasomedical EECP Therapy for 2008.
Vasomedical Reports Second Quarter Fiscal 2008 Financial Results.(Financial report)
Vasomedical Awarded New Patent for Automatic Regulation of Pressure During EECP(R) Therapy.
Vasomedical Reports Fiscal Year 2008 Financial Results.(Financial report)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles